What we do Alkem Laboratories Ltd is a leading Indian pharmaceutical company engaged in development, manufacture, and sale of branded generics, generics, APIs, and nutraceuticals globally. |
Founded in 1,973 |
Market share 5th largest pharma company in India with strong presence in anti-infectives, gastrointestinal, pain management, and chronic therapy segments. |
Problem solved Provides affordable, high-quality medicines across acute and chronic conditions addressing healthcare needs in India and international markets. |
Top clients or who we serve Serves patients via doctors and pharmacies; operates in B2B and B2C markets including India, US, Australia, Latin America, and Asia. |
Key management Sandeep Singh - Managing Director; Dr. Vikas Gupta - CEO; Nitin Agrawal - CFO; Manish Narang - President Legal; leadership with global pharmaceutical experience. |
Our journey and innovations Established in 1973, IPO in 2015; pioneered India’s first Rs 100 crore anti-infective; expanded into US generics, biosimilars, and global markets; continual R&D investment. |
Where we operate India, United States, Australia, Latin America, Europe, and other global markets with 29 subsidiaries and multiple manufacturing/R&D sites. |
Top products or what we offer Branded generics, generic drugs, APIs, biosimilars, and nutraceuticals; new launches in respiratory and chronic segments; CDMO services in the US. |
Top brands Taxim - historic Rs 100 crore anti-infective; Clavam - Rs 200 crore+ domestic sales; Metanext for chronic therapies; flagship brands across multiple therapies. |
Raw materials needed Active pharmaceutical ingredients, chemical intermediates, and biotechnological raw materials for generics and biosimilars. |
Raw materials supplier Sourced globally from specialized API and chemical suppliers compliant with quality standards. |
Recurring vs cyclical contribution Revenue driven by recurring sales of pharmaceutical products with steady demand; moderate cyclicality due to regulatory approvals. |
Our industry position Among top 5 in India, strong US generics footprint; growing biosimilars portfolio; recognized for robust R&D and compliance standards. |
Financial highlights FY25 consolidated revenue Rs 12964.5 crore; net profit Rs 2165.5 crore; 13% revenue growth; EBITDA margin ~23%; steady profitability improvement. |
Geographical revenue split India 70%, US 19%, other countries 11%; strong growth in international markets led by US and Australia. |
Order book - |
Whats driving growth New product launches, strong domestic market share, expanding ANDA pipeline in the US, increased biosimilar development, and international expansion. |
Our future plans Scaling biosimilars, expanding US ANDA filings, entering medtech, digital healthcare initiatives, and enhancing manufacturing capacity. |
Our green promise Focus on sustainability, solar power adoption, and community health initiatives aligned with CSR policy. |
Our people and values Over 12,500 employees fostering inclusive culture with emphasis on innovation, ethics, and patient-centric values. |
Key challenges ahead Regulatory compliance, intense competition in generics, managing supply chains, and navigating global market uncertainties. |
Interesting facts First Indian anti-infective crossing Rs 100 crore; extensive ANDA filings—over 180 with USFDA; 50+ years legacy. |
Risks and strategy Mitigates regulatory risks via compliance; robust R&D for pipeline; diversification across geographies and therapy areas; focus on quality and innovation. |
